Urgent health risks from Airborne viruses; How UV Flu Technologies, Inc. (OTCBB: UVFT innovative new air purification technology is more effective than filtering
Point Roberts WA - November 30, 2010 – www.Investorideas.com, an investor research portal
specialized in sector investing, issues biotech stocks commentary by Lisa Springer, CFA, equity
research analyst and financial writer. The report entitled,' Urgent Health Threat from Airborne
Viruses ‘, features UV Flu Technologies, Inc. (OTCBB: UVFT) and its air purification technology.
Urgent Health Threat from Airborne Viruses
Lisa Springer, CFA, Equity research analyst and financial writer
There is an urgent health threat deadlier than the H1N1 pandemic on the rise, yet few Americans
are aware of it. The threat comes from infections acquired while in the hospital. According to a
recent government study, America's hospitals aren't adequately protecting patients from these
potentially deadly infections. A 2009 report by the US Health and Human Services department
found little progress has been made over the past decade in eliminating hospital-acquired
infections and urged Congress to take action.
As many as 98,000 Americans die each year from medical errors and preventable infections are
a major contributor to the problem. Ten years ago, the Institute of Medicine launched a campaign
to stamp out hospital-acquired infections, but the success of their initiatives has been minimal.
The latest report showed three of five major types of hospital-acquired infections have actually
become more prevalent, one showed no progress and only one declined. Bloodstream infections,
which are considered the most serious and potentially fatal, rose 8.0 percent. There was also
a sizable 3.6 percent increase in the incidence of urinary tract infections. While generally
responsive to antibiotics, urinary tract infections increase hospitalization time and costs. Overall,
the incidence of common hospital-acquired infections was up 1.6 percent.
Media coverage of hospital-acquired infections, the swine flu pandemic and antibiotic resistant
superbugs is raising consumer awareness and spurring government agencies and businesses
to take action to safeguard public health. Demand for products that prevent the spread of
airborne illnesses is rising exponentially. The swine flu pandemic created a $7 billion windfall for
vaccine manufacturers, according to the Wall Street Journal, and a bonanza for makers of hand
sanitizers, who experienced a 129% jump in shipments during last year's flu season.
This heightened awareness is also spreading to the nearly $8 billion annual market for indoor air
quality products. These products improve air quality in commercial buildings, hospitals, schools
and homes by removing airborne pathogens. Scientific studies show poor indoor air quality is
a major reason for the spread of infectious disease. According to the Environmental Protection
Agency, the air inside buildings where people spend 90% of their time now poses a greater threat
than outdoor air.
Most air quality systems use a simple filter (either standard or HEPA) to trap pathogens.
Well-known filter device manufacturers include Pall Corp (NYSE: PLL), Donaldson Company
(NYSE: DCI) and Millipore, which was recently acquired by Merck KGaA. A relative newcomer
to this market, UV Flu Technologies, Inc. (OTCBB: UVFT), has developed an innovative new air
purification technology that is more effective than filtering. This technology disinfects indoor air
by deactivating allergens and killing airborne pathogens, including bacteria, viruses and mold.
UV Flu Technologies flagship product, the ViraTech UV-400, uses high intensity germicidal UV
radiation inside a killing chamber to trap and destroy harmful microbes. Extensive independent
testing by EPA and FDA certified laboratories confirms UV Flu Technologies system captures and
kills airborne bacteria and viruses at rates exceeding 99.2% on a first pass basis. The technology
is so effective that UV Flu Technologies was able to secure a Class II medical listing enabling it to
market its product as a medical device.
Since introducing its flagship device less than one year ago, UV Flu Technologies has sold
units to multiple sports teams, hospitals, restaurants and other commercial customers. Two
professional hockey teams (including the renowned Boston Bruins) and numerous college
teams have installed ViraTech UV-400 units in their locker rooms. In addition, the company has
installed units at two major hospitals and has units being evaluated by a large nursing home
chain. Hospitality customers such as The Seagate Hotel and Spa in Delray Beach, Florida, the
Boston Harbor Hotel and Boston's XV Beacon Hotel have installed ViraTech UV-400 units and
one of the nation's largest 5 star hotels is evaluating the unit for its operations. Tests of units
are also underway with one of the largest hotel and restaurant suppliers in the Northeast. In
addition, "Clean Air for Everyone," a non-profit promoting clean air for schools and non-profits
across America recently selected the ViraTech UV-400 as its lead product for national rollout.
UV Flu Technologies plans to expand its product line and distribution capabilities by acquiring
a major US manufacturer of high quality air purification equipment. The company hopes to
complete the merger this year. Included in the agreement is a patented product line, national
distribution network, and installed base of several thousand units across 1,000 unique facilities
nationwide. UVFT President Jack Lennon notes that the expanded product line will make the
company more attractive to large US distributors and improve its visibility in the hospital, hotel
and casino markets. UV Flu Technologies is also expanding its sales channels by adding three
new distributors. The new distributors are Emerald Medical Service, a supplier of medical
equipment serving the Washington, DC area; UV Air, a supplier to government, schools,
and hotels in Massachusetts and Factory-Direct Green, a distributor servicing over 400 hotel
customers in California.
Lisa Springer, CFA -Bio and disclaimer: http://www.investorideas.com/About/Lisa-Springer-CFA/
The author, Lisa Springer, was compensated for writing this article and doesn't own shares of any
of the companies mentioned in this article.
About UV Flu Technologies, Inc. (OTCBB: UVFT)
UV Flu Technologies is an innovative developer, manufacturer and distributor of bio technology
products initially targeting the rapidly growing Indoor Air Quality ("IAQ") industry sector (over
$7.7 billion in 2008). The Company manufactures the ViraTech UV-400, which utilizes high-
intensity ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to
destroy harmful airborne bacteria, at rates exceeding 99.2% on a first-pass basis, while also
reducing the concentrations of odors, and VOC's (volatile organic compounds, such as acetone,
benzene, formaldehyde, etc.) The FDA has issued a coveted Class II medical listing that enables
UV Flu Technologies to market the product as a medical device. For more information, visit:
www.uvflutech.com. For sales: www.puravair.com.
Read the forward looking statements disclaimer on all company press releases and company
UV Flu Technologies (OTCBB: UVFT) is a showcase biotech stock on Investorideas.com
Visit the showcase page on Investorideas.com
UV Flu Technologies, Inc.
Geaux IR Services, Inc.
InvestorIdeas.com is a leading global investor and industry research resource portal specialized
in sector investing, covering leading industry sectors including biotech stocks.
Research more biotech stocks at the Biotech stocks Directory:
Disclaimer: The following news is paid for by third party on behalf of UV Flu Technologies, Inc.,
(three thousand per month) Lisa Springer CFA- Investorideas compensated three hundred fifty
for article. Investorideas.com is a third party publisher of news and research .Our sites do not
make recommendations, but offer information portals to research news, articles, stock lists and
recent research. Nothing on our sites should be construed as an offer or solicitation to buy or
sell products or securities. This site is currently compensated by featured companies, news
submissions and online advertising.
firstname.lastname@example.org 800 665 0411
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.